Heart transplant recipient clinical profile improvement following mycophenolate mofetil late incorporation into the treatment schedule
| Autor: | Eduardo Castells, Josep Roca, Edgardo Kaplinsky, Enrique Esplugas, E Saura, Joan Antoni Gómez-Hospital, Nicolás Manito |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.medical_treatment Urology Azathioprine Mycophenolate Mycophenolic acid Drug Administration Schedule chemistry.chemical_compound Postoperative Complications Prednisone Medicine Humans Aged Retrospective Studies Heart transplantation Transplantation Creatinine business.industry Middle Aged Mycophenolic Acid medicine.disease Surgery Treatment Outcome chemistry Heart Transplantation Female business Immunosuppressive Agents medicine.drug Kidney disease |
| Zdroj: | Clinical transplantation. 19(3) |
| ISSN: | 0902-0063 |
| Popis: | Mycophenolate mofetil (MMF) has a better clinical profile than azathioprine in heart transplantation (HT). Forty-five recipients (aged 53 +/- 9 yr) were retrospectively evaluated (first year of follow-up) post-MMF introduction since its advent in 1997 (mean daily dose: 1.97 +/- 0.2 g). MMF was used (mean post-HT time: 40 +/- 27 months) for: (i) renal insufficiency attenuation (group 1 = 20); (ii) steroid reduction because of osteoporosis (group 2 = 12); (iii) treatment of persistent cellular rejection (group 3 = 7) and vascular graft disease (VGD) (group 4 = 6). Mean changes (groups 1-2) were: creatinine 172 +/- 59, 158 +/- 51, 153 +/- 57 mumol/L (at baseline, 6 and 12 months, respectively; p < 0.001). Cyclosporine daily dose: 219 +/- 37, 166 +/- 46, 176 +/- 98 mg, respectively (p < 0.001). Cyclosporine blood concentration: 151 +/- 40, 103 +/- 41, 83 +/- 34 ng/mL, respectively (p < 0.004). Prednisone daily dose: 8.3 +/- 2, 5.2 +/- 1, 4.1 +/- 1 mg, respectively (p < 0.001). Cellular rejection (group 3) was successfully treated (86%) but the outcome of VGD did not improve after the switch (group 4). Our limited experience (with caution) confirms the reported benefits of MMF particularly attenuating renal insufficiency. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|